Conversely, in other forms of cancer, SASP contributes to cancer progression by the release of factors like IL-6 and IL-1α [71] as well as by other mechanisms including induction of epithelial–mesenchymal transition [77], mTOR activation[78], recruitment of immature myeloid cells [79], or induction of the checkpoint molecule PD-L1 [80]. This evidence concerns the gene MTOR and cancer.